Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Survival Benefit of Perioperative Chemotherapy in Patients with Locally Advanced Gastric Cancer: a Propensity Score Matched Analysis

  • Eom, Bang Wool (Center for Gastric Cancer, Research Institute and Hospital, National Cancer Center) ;
  • Kim, Sohee (Biometric Research Branch, Research Institute for National Cancer Control and Evaluation, National Cancer Center) ;
  • Kim, Ja Yeon (Center for Gastric Cancer, Research Institute and Hospital, National Cancer Center) ;
  • Yoon, Hong Man (Center for Gastric Cancer, Research Institute and Hospital, National Cancer Center) ;
  • Kim, Mi-Jung (Center for Gastric Cancer, Research Institute and Hospital, National Cancer Center) ;
  • Nam, Byung-Ho (Biometric Research Branch, Research Institute for National Cancer Control and Evaluation, National Cancer Center) ;
  • Kim, Young-Woo (Center for Gastric Cancer, Research Institute and Hospital, National Cancer Center) ;
  • Park, Young-Iee (Center for Gastric Cancer, Research Institute and Hospital, National Cancer Center) ;
  • Park, Sook Ryun (Center for Gastric Cancer, Research Institute and Hospital, National Cancer Center) ;
  • Ryu, Keun Won (Center for Gastric Cancer, Research Institute and Hospital, National Cancer Center)
  • Received : 2018.01.30
  • Accepted : 2018.03.22
  • Published : 2018.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: It has been reported that the survival of patients with locally advanced gastric cancer (LAGC) is better in East Asia countries than in developed western countries; however, the prognosis of LAGC remains poor. This study aimed to evaluate the effects of perioperative chemotherapy on the long-term survival of East Asia patients with LAGC. Materials and Methods: From October 2006 through August 2008, 43 patients with LAGC received perioperative S-1 combined with weekly docetaxel in a phase II study (neoadjuvant group). These patients were matched using propensity scores to patients who underwent surgery without neoadjuvant chemotherapy during the same period (surgery group). The surgical outcomes and long-term survivals were compared between the 2 groups. Results: After matching, 43 and 86 patients were included in the neoadjuvant and surgery groups, respectively, and there was no significant difference in their baseline characteristics. Although the operating time was longer in the neoadjuvant group, there was no significant difference in postoperative complications between the 2 groups. The neoadjuvant group had a significantly higher 5-year overall survival (OS) rate (73.3% vs. 51.1%, P=0.005) and a trend towards higher 5-year progression-free survival (PFS) (62.8% vs. 49.9%, P=0.145). In the multivariate analysis, perioperative chemotherapy was an independent factor for OS, with a hazard ratio of 0.4 (P=0.005) and a marginal effect on the PFS (P=0.054). Conclusions: Perioperative chemotherapy was associated with better long-term survival without increasing postoperative complications in the setting of D2 surgery for patients with LAGC, suggesting that perioperative chemotherapy can be a therapeutic option in East Asia countries.

Keywords

References

  1. Strong VE, Song KY, Park CH, Jacks LM, Gonen M, Shah M, et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg 2010;251:640-646. https://doi.org/10.1097/SLA.0b013e3181d3d29b
  2. Jeong O, Park YK. Clinicopathological features and surgical treatment of gastric cancer in South Korea: the results of 2009 nationwide survey on surgically treated gastric cancer patients. J Gastric Cancer 2011;11:69-77. https://doi.org/10.5230/jgc.2011.11.2.69
  3. Nashimoto A, Akazawa K, Isobe Y, Miyashiro I, Katai H, Kodera Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer 2013;16:1-27. https://doi.org/10.1007/s10120-012-0163-4
  4. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20. https://doi.org/10.1056/NEJMoa055531
  5. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29:1715-1721. https://doi.org/10.1200/JCO.2010.33.0597
  6. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820. https://doi.org/10.1056/NEJMoa072252
  7. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-321. https://doi.org/10.1016/S0140-6736(11)61873-4
  8. Yoon HM, Ryu KW, Nam BH, Cho SJ, Park SR, Lee JY, et al. Is the new seventh AJCC/UICC staging system appropriate for patients with gastric cancer? J Am Coll Surg 2012;214:88-96.
  9. Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:1389-1396. https://doi.org/10.1016/S1470-2045(14)70473-5
  10. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29:4387-4393.
  11. Chun J, Park S, Kim H, Kim Y, Ryu K, Lee J, et al. Randomized phase II trial of neoadjuvant vs. adjuvant docetaxel plus cisplatin in patients with locally advanced gastric carcinoma: an interim analysis. J Clin Oncol 2006;24 suppl:abstr 4030.
  12. Kim YW, Kim MJ, Ryu KW, Lim HS, Lee JH, Kong SY, et al. A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival. Gastric Cancer 2016;19:586-596. https://doi.org/10.1007/s10120-015-0490-3
  13. Fujitani K, Sasako M, Iwasaki Y, Yoshimura K, Sano T, Nashimoto A, et al. A phase II study of preoperative chemotherapy (CX) with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancer: JCOG 0210. J Clin Oncol 2007;25 suppl:abstr 4609.
  14. Yoshikawa T, Sasako M, Yamamoto S, Sano T, Imamura H, Fujitani K, et al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg 2009;96:1015-1022. https://doi.org/10.1002/bjs.6665
  15. Yoshikawa T, Nakamura K, Tsuburaya A, Sano T, Mizusawa J, Katai H, et al. A phase II study of preoperative chemotherapy with S-1 (S) and cisplatin (P) followed by D3 gastrectomy for gastric cancer (GC) with extensive lymph node metastasis (ELM): survival results of JCOG 0405. J Clin Oncol 2011;29 suppl:abstr 70.
  16. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 2nd English edition. Gastric Cancer 1998;1:10-24. https://doi.org/10.1007/PL00011681
  17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216. https://doi.org/10.1093/jnci/92.3.205
  18. Kim SK, Kang KW, Lee JS, Kim HK, Chang HJ, Choi JY, et al. Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer. Eur J Nucl Med Mol Imaging 2006;33:148-155. https://doi.org/10.1007/s00259-005-1887-8
  19. Nakajima T. Gastric cancer treatment guidelines in Japan. Gastric Cancer 2002;5:1-5.
  20. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383. https://doi.org/10.1016/0021-9681(87)90171-8
  21. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619. https://doi.org/10.1016/0895-4356(92)90133-8
  22. Aaltonen LA, Hamilton SR; World Health Organization. Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC Press, 2000.
  23. Sobin LH. TNM Classification of Malignant Tumours. 6th ed. New York (NY): John Wiley, 2002.
  24. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205-213. https://doi.org/10.1097/01.sla.0000133083.54934.ae
  25. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2011;10:150-161. https://doi.org/10.1002/pst.433
  26. Park I, Ryu MH, Choi YH, Kang HJ, Yook JH, Park YS, et al. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma. Cancer Chemother Pharmacol 2013;72:815-823. https://doi.org/10.1007/s00280-013-2257-z
  27. Kosaka T, Akiyama H, Makino H, Takagawa R, Kimura J, Ono H, et al. Preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer. Cancer Chemother Pharmacol 2014;73:281-285. https://doi.org/10.1007/s00280-013-2350-3
  28. Hirakawa M, Sato Y, Ohnuma H, Takayama T, Sagawa T, Nobuoka T, et al. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker. Cancer Chemother Pharmacol 2013;71:789-797. https://doi.org/10.1007/s00280-013-2073-5
  29. Takiguchi N, Nunomura M, Koda K, Oda K, Suzuki H, Miyazaki M. Neoadjuvant chemotherapy with CDDP and 5-fluorouracil for gastric cancer with serosal invasion. Oncol Rep 2003;10:433-438.
  30. Kang YK, Choi DW, Im YH, Kim CM, Lee JI, Moon NM, et al. A phase III randomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer. J Clin Oncol 1996;15 suppl:abstr 503.
  31. Li ZY, Shan F, Zhang LH, Bu ZD, Wu AW, Wu XJ, et al. Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer. World J Surg Oncol 2011;9:110. https://doi.org/10.1186/1477-7819-9-110
  32. Ahn HS, Jeong SH, Son YG, Lee HJ, Im SA, Bang YJ, et al. Effect of neoadjuvant chemotherapy on postoperative morbidity and mortality in patients with locally advanced gastric cancer. Br J Surg 2014;101:1560-1565. https://doi.org/10.1002/bjs.9632

Cited by

  1. ZNF139 increases multidrug resistance in gastric cancer cells by inhibiting miR-185 vol.38, pp.5, 2018, https://doi.org/10.1042/bsr20181023
  2. BATF2 reverses multidrug resistance of human gastric cancer cells by suppressing Wnt/β-catenin signaling vol.55, pp.6, 2019, https://doi.org/10.1007/s11626-019-00360-5
  3. The Efficacy Analysis in the Treatment of Advanced Gastric Cancer with Neoadjuvant Chemotherapy vol.10, pp.7, 2018, https://doi.org/10.12677/acm.2020.107207
  4. A Modified ypTNM Staging System–Development and External Validation of a Nomogram Predicting the Overall Survival of Gastric Cancer Patients Received Neoadjuvant Chemotherapy vol.12, pp.None, 2018, https://doi.org/10.2147/cmar.s236696
  5. Perioperative chemotherapy for advanced gastric cancer - results from a tertiary-care hospital in Germany vol.12, pp.5, 2018, https://doi.org/10.4251/wjgo.v12.i5.559
  6. Postprandial Changes in Gastrointestinal Hormones and Hemodynamics after Gastrectomy in Terms of Early Dumping Syndrome vol.20, pp.3, 2018, https://doi.org/10.5230/jgc.2020.20.e24
  7. Does Neoadjuvant Chemotherapy Increase the Survival in Patients with Locally Advanced Gastric Cancer Patients? - A Real‑World Evidence vol.41, pp.6, 2018, https://doi.org/10.4103/ijmpo.ijmpo_188_20